A Multicenter, Open-label Study of Harvoni ® (Sofosbuvir Ledipasvir Fixed Dose Combination) in Subjects Infected With Chronic Hepatitis C and Advanced Heart Failure or Lung Disease
Latest Information Update: 22 Apr 2020
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 23 Jul 2019 Status changed from recruiting to completed.
- 18 Dec 2018 Planned End Date changed from 1 Dec 2018 to 1 Apr 2019.
- 18 Dec 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Apr 2019.